From raw measurements to human pose - a dataset with low-cost and high-end inertial-magnetic sensor data.

Wearable technology is expanding for motion monitoring. However, open challenges still limit its widespread use, especially in low-cost systems. Most solutions are either expensive commercial products or lower performance ad-hoc systems. Moreover, few datasets are available for the development of complete and general solutions. This work presents 2 datasets, with low-cost and high-end Magnetic, Angular Rate, and Gravity(MARG) sensor data. Provides data for the complete inertial pose pipeline analysis, starting from raw data, sensor-to-segment calibration, multi-sensor fusion, skeleton-kinematics, to complete Human pose. Contains data from 21 and 10 participants, respectively, performing 6 types of sequences, presenting high variability and complex dynamics with almost complete range-of-motion. Amounts to 3.5 M samples, synchronized with a ground-truth inertial motion capture system. Presents a method to evaluate data quality. This database may contribute to develop novel algorithms for each pipeline's processing steps, with applications in inertial pose estimation algorithms, human movement forecasting, and motion assessment in industrial or rehabilitation settings. All data and code to process and analyze the complete pipeline is freely available.

The manganese(III) porphyrin MnTnHex-2-PyP5+ modulates intracellular ROS and breast cancer cell migration: Impact on doxorubicin-treated cells.

Manganese(III) porphyrins (MnPs) are superoxide dismutase (SOD) mimics with demonstrated beneficial effects in cancer treatment in combination with chemo- and radiotherapy regimens. Despite the ongoing clinical trials, little is known about the effect of MnPs on metastasis, being therefore essential to understand how MnPs affect this process. In the present work, the impact of the MnP MnTnHex-2-PyP5+ in metastasis-related processes was assessed in breast cancer cells (MCF-7 and MDA-MB-231), alone or in combination with doxorubicin (dox). The co-treatment of cells with non-cytotoxic concentrations of MnP and dox altered intracellular ROS, increasing H2O2. While MnP alone did not modify cell migration, the co-exposure led to a reduction in collective cell migration and chemotaxis. In addition, the MnP reduced the dox-induced increase in random migration of MDA-MB-231 cells. Treatment with either MnP or dox decreased the proteolytic invasion of MDA-MB-231 cells, although the effect was more pronounced upon co-exposure with both compounds. Moreover, to explore the cellular mechanisms underlying the observed effects, cell adhesion, spreading, focal adhesions, and NF-κB activation were also studied. Although differential effects were observed according to the endpoints analysed, overall, the alterations induced by MnP in dox-treated cells were consistent with a therapeutically favorable outcome.

Comparative Study Between Tuberculosis Incidence Rates in the Two Largest Metropolitan Areas of Portugal / Estudio comparativo de la incidencia de tuberculosis en las dos áreas metropolitanas más grandes de Portugal

No disponible

Role of the Copper(II) Complex Cu[15]pyN5 in Intracellular ROS and Breast Cancer Cell Motility and Invasion.

Multiple mechanisms related to metastases undergo redox regulation. Cu[15]pyN5 is a redox-active copper(II) complex previously studied as a chemotherapy sensitizer in mammary cells. The effects of a cotreatment with Cu[15]pyN5 and doxorubicin (dox) were evaluated in two human breast cancer cell lines: MCF7 (low aggressiveness) and MDA-MB-231 (highly aggressive). Cu[15]pyN5 decreased MCF7-directed cell migration. In addition, a cotreatment with dox and Cu[15]pyN5 reduced the proteolytic invasion of MDA-MB-231 cells. Cell detachment was not affected by exposure to these agents. Cu[15]pyN5 and dox significantly increased intracellular ROS in both cell lines. This increase could be at least partially due to H2 O2 accumulation. The combination of Cu[15]pyN5 with dox may be beneficial in breast cancer treatment as it could help reduce cancer cell migration and invasion. Moreover, the ligand [15]pyN5 has a high affinity for copper(II) and displays potential anti-angiogenic properties. Overall, we present a potential drug that might arrest the progression of breast cancer by different and complementary mechanisms.